Summit Therapeutics says its partner Akeso will share new results from a big trial at a conference.

Sep 14, 2026, 8:47 AM ETTrialRead the original at sec.gov

Neutral

Summit filed an 8-K saying its partner will present updated Phase III HARMONi-2 data, including overall survival, at a lung cancer conference. The filing includes no results, so it does not change how we read Summit today.

SMMT · Summit Therapeutics Inc.

AI read · Neutral

The AI's read

Summit Therapeutics filed an 8-K saying its partner Akeso will present updated Phase III HARMONi-2 data, including overall survival, at a lung cancer conference. The filing attaches a press release but gives no trial numbers or results, so the report by itself does not change how we read Summit today.

Get alerts for SMMT

Follow Summit Therapeutics Inc. (SMMT) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for SMMT

Free on the App Store and Google Play, or on the web.